Patients with non‑small cell lung cancer with the exon 21 L858R ...
Aiming for precision medicine, the present review introduces and compares different EGFR-TKIs for the ex21 L858R mutation to assess more personalized treatment options for the population with this …
What Is the EGFR L858R Mutation in Lung Cancer?
Nov 17, 2025 · Understand the EGFR L858R mutation in lung cancer, its biological significance, and how this biomarker determines effective targeted treatment strategies.
EGFR L858R: Diagnosis, Treatment, and Prognosis
Jul 27, 2025 · The EGFR L858R mutation is a genetic alteration observed in certain cancers, particularly non-small cell lung cancer (NSCLC). This genetic change involves a single “point” mutation in the …
L858R emerges as a potential biomarker predicting response of lung ...
Aug 8, 2023 · The reviewed observations predicted that cetuximab would inhibit tumors carrying the L858R mutation, but lung tumors expressing other EGFR mutants will show no responses.
Spandidos Publications: Oncology Letters
Dec 20, 2024 · Aiming for precision medicine, the present review introduces and compares different EGFR‑TKIs for the ex21 L858R mutation to assess more personalized treatment options for the …
Double-dose firmonertinib as first-line treatment in patients with ...
Jan 19, 2026 · Double-dose firmonertinib shows promising efficacy and tolerability, supporting its preliminary potential as first-line treatment for EGFR L858R-mutated advanced NSCLC.
How L858R Alters Lung Cancer Growth and Division
Apr 29, 2025 · Among these, the L858R mutation in the epidermal growth factor receptor (EGFR) gene is a well-documented alteration in non-small cell lung cancer (NSCLC). This substitution significantly …
Acquired EGFR L858R mutation following ALK-TKI resistance in lung ...
Mar 5, 2026 · Upon further disease progression, a lung biopsy and next-generation sequencing (NGS) revealed acquired secondary driver mutations including Epidermal Growth Factor Receptor (EGFR) …
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
Here the authors aim to highlight the differences between the most common EGFR subtypes and the clinical implications as well as discuss how we can improve outcomes for patients with the exon 21 …
L858R emerges as a potential biomarker predicting response of lung ...
Aug 15, 2023 · These results identify L858R as a predictive biomarker, which may pave the way for relapse-free mAb monotherapy relevant to a large fraction of patients with lung cancer.